(PRNewswire) IQM Quantum Computers (IQM) announced that BioNTech Chairman Helmut Jeggle has joined IQM´s board of directors. He joins the company during a transformational phase. After successfully closing its Series A funding round and selling its first quantum computer, IQM is now ready to lead the European and global ecosystems with a focus on Germany.
Helmut Jeggle joins IQM at a critical juncture in the company’s development following his investment in the company as part of the series A financing round in 2020 via his investment vehicle Salvia GmbH. With the recent financing round, IQM is in a leading position to build a quantum computer in Germany and create value through its novel co-design approach.
“The amount of data that needs to be processed is one of the limiting factors in many industries. Quantum computers and alternate technologies provide the opportunity to leverage big data more rapidly and efficiently. One exciting application could also be to accelerate and streamline drug development processes. IQM is already building Finland’s first quantum computer and is also the leading system integrator in Europe.
“I am extremely excited that Helmut has accepted our invitation to join IQM’s board of directors. He has an established track record in building technology businesses and brings in decades of experience in creating global tech giants. He was closely involved in Hexal’s business and he has supported BioNTech on its journey towards establishing itself as a global company for more than a decade. We look forward to his contributions in maximizing the potential of IQM and become a global leader for quantum computers,” said Jan Goetz, CEO of IQM.
Helmut Jeggle held various positions with Hexal AG, including Head of Business Planning & Analyses. He is General Manager of ATHOS Service GmbH, the Strüngmann brothers’ family office and also a member of numerous supervisory boards.
Helmut joins the IQM board, which is chaired by Dr. Axel Thierauf. Other board members include Dr. Mikko Välimäki, Herbert Mangesius, and Dr. Kuan Yen Tan.